NCT00131742已完成3 期
A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 试验地点
- 1
研究概览
简要总结
This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 16 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented clinical history compatible with chronic hepatitis B infection
- •Other protocol-defined inclusion criteria may apply
排除标准
- •Patient is pregnant or breastfeeding
- •Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV
- •Patient has previously received lamivudine or any investigational anti-HBV nucleoside or nucleotide analog
- •Other protocol-defined exclusion criteria may apply
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.CirrhosisHepatitis BNCT00275652Mayo Clinic6
已完成
3 期
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis BChronic Hepatitis BNCT00057265Novartis
已完成
3 期
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of CirrhosisHepatitis B, ChronicHepatitisCirrhosisNCT00076336Novartis Pharmaceuticals232
已完成
3 期
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis BChronic Hepatitis BNCT00115245Novartis
已完成
2 期
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV DrugsHIV InfectionsNCT00004852Glaxo Wellcome